Nymox Announces Positive Prostate Cancer 8 Month Clinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nymox Announces Positive Prostate Cancer 8 Month Clinical Trial Results

HASBROUCK HEIGHTS, N.J., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq: NYMX ) announced today new positive outcome results from the Company's ongoing prospective NX03-0040 trial of NX-1207 for the treatment of low grade localized prostate cancer. Clinical outcomes were determined at 8 months from the initial treatments. A controlled comparison was conducted of patients who required and received radiation and surgery treatments for their cancer based on blinded post-treatment upgraded evaluations of their pre-treatment initially positive lower grade cancers. The study found after 8 months for NX-1207 single-injection treated patients that there was a statistically significant reduction compared to controls of more than 75% (p=.002) in the proportion of patients who had upgraded blinded biopsy and laboratory results and went on to require and receive radiation therapy and/or surgery. The new results also indicated that the NX-1207 treated patients had 67% less progression to surgery and/or radiotherapy compared to controls (p=.008) for all reasons (including elective surgery and/or radiotherapy with no biopsy or laboratory upgrades).

146 patients were enrolled in the NX03-0040 Phase 2 U.S. trial and either randomized to one of two doses of NX-1207 (2.5 mg or 15 mg) or to active surveillance. The drug was injected into the area of the prostate where the cancer was detected and repeat biopsies were then performed on all patients, drug treated and controls. The patients in the active surveillance group in the study who were eligible could elect crossover drug treatment after their first follow-up rebiopsy. Follow-up studies are being conducted of all consenting patients in the study to continue to monitor outcome and safety data.

These new findings extend the previously reported study results which showed that patients with NX-1207 treatment after 2 months had less clinical progression and significantly less Gleason grade progression, lower average PSA levels, lower numbers of biopsy cores showing greater malignancy, and lower total volume of more malignant cancer compared to controls.

To date, NX-1207 has had an excellent safety profile as both a treatment for benign prostatic hyperplasia (BPH) and localized low-risk prostate cancer. In the current trial, a new high dose of drug (15 mg) was safely used without drug-related adverse effects. NX-1207 has shown safety in repeat injection studies (NX02-0020 and NX02-0022). The drug does not lead to immune responses such as antibody formation which can cause significant drug toxicity and/or limit usage to single treatments due to drug neutralizing effects.

Prostate cancer is the most commonly diagnosed cancer in men, other than skin cancer, and is the second leading cause of cancer death for men. An estimated 233,000 cases will be newly diagnosed in the U.S. in 2014 with approximately 50% of them being initially considered low risk.

NX-1207 is in Phase 3 development in the US and Europe for benign prostatic hyperplasia (BPH) also referred to as prostate enlargement, a common condition of middle-aged and elderly men affecting up to half of men over the age of 50. The Company's European partner for BPH is Recordati S.p.A.

More information about Nymox is available at www.nymox.com , email: info@nymox.com , or 800-936-9669.

"This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Factors that could cause actual results or events to differ materially from those projected in forward-looking statements are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities."

For Further Information Contact: Brian Doyle Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 89

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 63

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 99

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 97

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 36

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 16

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 50

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 63

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 54

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover AM Best's New Bookstore for Insurance Insights

Updated Category News Views 92

AM Best Unveils Innovative Bookstore for Insurance Readers AM Best recently launched the AM Best’s Bookstore, a unique digital platform designed for those interested in deeper insights into the insurance sector. This bookstore serves as a central hub for information on newly published books that cover a wide range of topics pertinent to the insurance industry....

Continue Reading
Aurora Mobile Hits a Milestone with Strong Q2 Financials

Updated Category News Views 174

Aurora Mobile Reports Impressive Second Quarter Financial Results Aurora Mobile Limited, recognized for its customer engagement and marketing technology services, has revealed its financial metrics for the second quarter of 2025. This quarter has marked a groundbreaking achievement with the company recording its inaugural quarterly net income under U.S. GAAP. Financial...

Continue Reading
Meta Platforms' Competitive Edge in Media and Services Sector

Updated Category News Views 279

Understanding Meta Platforms in its Industry Context In the fast-paced realm of Interactive Media & Services, comprehensive analysis is vital for both investors and market analysts. This article dives into an industry comparison, focusing on Meta Platforms (NASDAQ: META) along with its prominent competitors. By evaluating crucial financial indicators, market standings,...

Continue Reading
Investigation by Rosen Law Firm for Kaspi.kz Investors

Updated Category News Views 88

Rosen Law Firm's Investigation of Kaspi.kz Security Claims The Rosen Law Firm, globally recognized for protecting investor rights, has launched an investigation regarding potential securities claims for shareholders of Joint Stock Company Kaspi.kz (NASDAQ: KSPI). This investigation stems from serious allegations that Kaspi.kz may have disseminated misleading business...

Continue Reading
Praxis Precision Medicines to Showcase Innovations This Fall

Updated Category News Views 158

Upcoming Investor Conferences for Praxis Precision Medicines Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a dynamic entity in the field of biopharmaceuticals, has an exciting roster of events lined up this fall. The company is dedicated to developing therapies aimed at addressing central nervous system (CNS) disorders that are driven by imbalances in neuronal...

Continue Reading